RESCIMETOL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C33H38N2O8
Molecular Weight	590.6634
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12C[C@@H](OC(=O)\C=C\C3=CC=C(O)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]4([H])N(CCC5=C4NC6=C5C=CC(OC)=C6)C2

InChI

InChIKey=MMUMZMIKZXSFSD-ADSVITMPSA-N

InChI=1S/C33H38N2O8/c1-39-20-7-8-21-22-11-12-35-17-19-14-28(43-29(37)10-6-18-5-9-26(36)27(13-18)40-2)32(41-3)30(33(38)42-4)23(19)16-25(35)31(22)34-24(21)15-20/h5-10,13,15,19,23,25,28,30,32,34,36H,11-12,14,16-17H2,1-4H3/b10-6+/t19-,23+,25-,28-,30+,32+/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17027
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23346 and https://www.ncbi.nlm.nih.gov/pubmed/14871

Rescimetol (CD-3400) developed by Nippon Chemiphar Co. Ltd., is an antihypertensive agent belonging to the class of rauwolfa alkaloids. CD-3400 was shown to have low toxicity and a weak central action. CD-3400 possessing a sustained antihypertensive activity may be prescribed in cases when long-term therapy is required for hypertensive patients.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
smooth muscle contraction 13 Target ID: GO:0006939 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14872	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17027	Primary		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Effects of methyl o-(4-hydroxy-3-methoxycinnamoyl) reserpate (CD-3400) on erection and ejaculation in dogs].	1982 Sep	6130031

Patents

Sample Use Guides

In Vivo Use Guide

4-16 mg/kg p.o in rats Rescimetol (CD-3400), 5 mg/kg/day p.o. for 14 days, produced 25 to 30 mmHg fall in systolic blood pressure during the administrations, and blood pressure was returned to the pretreatment level within 5 days following withdrawal of the agent. The higher dose of CD-3400, 12 mg/ kg/day p.o., caused a more marked fall in systolic blood pressure by 40 to 50 mmHg during repeated administrations and the pressure returned to the pretreatment level more than 9 days following the withdrawal of the agent.

Route of Administration: Oral

In Vitro Use Guide

Rescimetol (CD-3400) at a concentration of 1 X 10(-5) M inhibited norepinephrine-induced contraction in isolated guinea pig vas deferens

Name

Type

Language

RESCIMETOL

Official Name

English

RESCIMETOL [MI]

Common Name

English

RESCIMETOL [JAN]

Common Name

English

rescimetol [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C270